Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228195 · ClinicalTrials.gov registry record · Phase 4
SGLT2i Therapy in Islet Transplantation (SIT)
A Phase 4 study, sponsored by University of Minnesota.
- Not yet
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT07228195 is a Phase 4 study that has not yet begun recruiting, run by University of Minnesota. The registered enrollment target is 40 participants.
The verdict
NCT07228195, a Phase 4 study, has not yet begun recruiting, sponsored by University of Minnesota.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.
Interventions
- DRUG Empagliflozin 25 MG Oral Tablet
- DRUG Empagliflozin 10 MG Oral Tablet [Jardiance]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07228195
The ClinicalTrials.gov registry entry for NCT07228195 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Empagliflozin 25 MG Oral Tablet is the first listed.
NCT07228195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07228195 about?
NCT07228195 is a clinical study titled "SGLT2i Therapy in Islet Transplantation (SIT)". This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.
What is the current status of trial NCT07228195?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2026-07-15. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT07228195?
The interventions under investigation include: Empagliflozin 25 MG Oral Tablet (DRUG), Empagliflozin 10 MG Oral Tablet [Jardiance] (DRUG).
Who is sponsoring clinical trial NCT07228195?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.